Leader’s in Alzheimer’s disease research, TauRx has a strong and defensible intellectual property position. Over the past 23 years of research in the tau pathology of Alzheimer’s disease, Professor Wischik’s team has generated a multi-layered portfolio of patents and patent applications which TauRx believes will permit a strong defensive intellectual property position. In particular, LMTX® is covered by a composition of matter patent which does not expire until 2027.
Having pioneered a new pathway towards effective treatment and prevention of Alzheimer’s, the company’s success to date is also due to collaborations with organisations that span a variety of fields. Achieving the company’s long term vision and commercial goals will require further alliances and TauRx is pleased to consider new potential collaborators and or partners from:
Should your company match the business development interests of TauRx as outlined above, please contact us